Arteriocyte, Inc., the research and development division of the Arteriocyte family of companies, announced today that they will begin doing business as Compass Biomedical. The name change and reorganization follow the recent acquisition of the orthopedic-focused division, Arteriocyte Medical Systems, Inc. (AMSI), including the Arteriocyte trademark by ISTO Technologies.
Compass Biomedical was founded in 2004 when a hematologist and a cardiologist teamed up to use a patient's own bone marrow-derived stem cells as treatment following a heart attack. Cellular therapy is the foundation of Compass Biomedical and continues to be the company's focus with their BioBandage™, PLUS™, and NANEX™ products.
Compass Biomedical has been a leader in the research and development of tools for adult stem cell therapies such as the NANEX™ platform for expansion of hematopoietic stem cells (HSCs) and the PLUS™ human platelet lysate product, which serves as a clinical grade replacement for fetal bovine serum in cell culture protocols. Since 2007, Compass has leveraged its strong research and development team to provide research and regulatory support to AMSI for product development and expansion of indications of its autologous cell concentrate therapies. BioBandage™, currently under clinical testing, is an autologous platelet rich plasma covering for wound care.
The reorganization allows Compass Biomedical to focus on developing platelet-derived products for cell culture, wound care, and ophthalmic applications and expand its core research and manufacturing capabilities as a new contract service provider to organizations in the space.
In alignment with the new DBA name, the company has launched a new logo and plans to reveal a new website by early 2017. The new logo features a strong letter C image with an unexpected twist reflecting Compass' innovative approach to research and product development through commercialization, collaboration, and commitment. The logo also includes a central star shape to represent exploration and discovery.
"The new name, Compass Biomedical, allows us to emphasize our commitment to our customers," said Compass Biomedical CEO, Don Brown. "Just as a compass is a tool that explorers use to find direction, we want our customers to trust that they can depend on Compass to guide them through the transition from research to the clinic by providing them with the best quality products and services."
About Compass Biomedical
Compass Biomedical is a leading biotechnology company focused on commercializing platelet-derived products for stem cell culture, wound care, and ophthalmic applications. Their core technology focuses on the commercialization of platelet products such as BioBandage™, a Magellan® platelet rich plasma product, and PLUS™ human platelet lysate which serves as a clinical grade cell culture supplement. The company leverages its solid research and development team to serve as a contract research and manufacturing services (CRAMS) provider for partners developing blood and platelet-derived cell therapies.
